A Study of NTX-1472 in Social Anxiety Disorder

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Social Anxiety Disorder (SAD)

In brief

The primary goal of this Phase 2 clinical trial is to determine the effects of a novel V1a receptor antagonist (NTX-1472) in adults with Social Anxiety Disorder (SAD). The main questions this trial aims to answer are: * Is NTX-1472 safe and well tolerated in adults with SAD? * How effectively does NTX-1472 treat adults with SAD? Researchers will compare the effects of NTX-1472 with matching placebo (a look-alike capsule that contains no drug). Participants will: * Take NTX-1472 or matching placebo every day for 8 weeks * Visit the clinic 6 times over the course of 14 weeks for checkups and tests

Key facts

Study ID: NCT07323784
Run by: Newleos Therapeutics, Inc.
People needed: 100
Starts: 2025-12-09
Expected to finish: 2027-01-01
Last updated by the study team: 2026-07-09

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

SOAR Clinical Study Site — Austin, Texas, United States (enrolling)
SOAR Clinical Study Site — Los Angeles, California, United States (enrolling)
SOAR Clinical Study Site — Oceanside, California, United States (enrolling)
SOAR Clinical Study Site — San Jose, California, United States (enrolling)
SOAR Clinical Study Site — Jacksonville, Florida, United States (enrolling)
SOAR Clinical Study Site — Tampa, Florida, United States (enrolling)
SOAR Clinical Study Site — Boston, Massachusetts, United States (enrolling)
SOAR Clinical Study Site — Encino, California, United States (enrolling)
SOAR Clinical Study Site — Brooklyn, New York, United States (enrolling)
SOAR Clinical Study Site — Memphis, Tennessee, United States (enrolling)
SOAR Clinical Study Site — Las Vegas, Nevada, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.